AI drug discovery firms raised about $3.8B, not one $3.8B startup

In short: The widely cited “$3.8 billion” figure is a total for money invested across many AI drug discovery companies, not the valuation of one startup.

What's going on

Some headlines and quotes have mixed up two different numbers, how much money investors put into a sector versus what one company is worth. Several industry reports say AI drug discovery companies collectively raised about $3.8 billion in venture capital across 2024 and 2025. That is like adding up everyone’s fundraising in a neighborhood, not pricing one house.

This matters because individual companies in the field are also raising very large rounds. The New York Times reported on Chai Discovery, which raised a Series B round and is being discussed by investors as potentially targeting a much higher valuation in a future raise. In other examples from recent coverage, Isomorphic Labs has announced very large financings, and Recursion Pharmaceuticals has raised money at a multi billion dollar valuation and has been active in acquisitions.

Money is also coming in through partnerships with big drug companies. These deals can include “potential deal value,” which is a maximum total if milestones are hit (similar to a bonus that only pays out if goals are met).

What to watch

Investors are betting that AI can help find drug candidates faster and filter out weak ones earlier, before expensive testing. The next sign to watch is whether these companies can turn funding and partnerships into successful medicines, since drug development still takes years and many attempts fail.

Source: NYTimes